AstraZeneca: European Medicines Agency Recommends Asthma Treatment Approval
November 10 2017 - 7:37AM
Dow Jones News
By Adam Clark
AstraZeneca PLC (AZN.LN) said Friday that the European Medicines
Agency has recommended the marketing authorization of its
benralizumab drug for asthma treatment.
The pharmaceutical company said the recommendation is based on
phase 3 clinical trial data and is an important step towards
providing a next-generation treatment for severe, uncontrolled
asthma patients.
The positive opinion will now be reviewed by the European
Commission, which has the authority to approve medicines for the
European Union. The drug is also under regulatory review in the
U.S., Japan and several other countries.
Shares are down 54 pence, or 1.1%, at 4908 pence at 1203
GMT.
Write to Adam Clark at adam.clark@dowjones.com;
@AdamDowJones
(END) Dow Jones Newswires
November 10, 2017 07:22 ET (12:22 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
